- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Wearable alert system for epileptics set for European launch | ||
| Do | Vaderis drug lends hope to patients with bleeding disease HHT | ||
| Do | Platform tests commercial algorithms for NHS use for bias | ||
| Do | FDA starts priority review of BeOne's Venclexta rival | ||
| Do | Lundbeck bows out of bidding war for Avadel | ||
| Mi | Novo Nordisk spends priority voucher on Wegovy filing | ||
| Mi | Sanofi's Paris HQ raided in tax fraud probe | ||
| Mi | Kelonia's in vivo CAR-T data will feature at ASH | ||
| Mi | Otsuka joins IgAN market with Voyxact approval in US | ||
| Mi | Latest Medicare pricing cuts promise $12bn in savings | ||
| Di | Data sets up phase 3 trials for Novo's amycretin in diabetes | ||
| Di | NICE backs NHS use of Autolus' leukaemia CAR-T | ||
| Di | £800m life sciences cluster opens in London | ||
| Di | Innovent files high-dose mazdutide for obesity in China | ||
| Di | Novartis' SMA gene therapy cleared for wider use in US | ||
| Mo | Angelini rapped for criticism of EMA approval | ||
| Mo | Disappointment as Novo's oral GLP-1 fails in Alzheimer's | ||
| Mo | Stroke data breathes life back into Bayer's asundexian | ||
| Mo | J&J abandons Alzheimer's antibody in setback for tau | ||
| Mo | Lilly becomes first $1trn+ pharma company | ||
| 21.11. | Waltz dances into direct-to-employer sales of obesity drugs | ||
| 21.11. | Neuralink rival Paradromics cleared to start speech trial | ||
| 21.11. | Alnylam's ATTR cardiomyopathy drug backed for NHS use | ||
| 21.11. | ADC specialist Solve raises $120m, and other biofinancings | ||
| 21.11. | GSK unit and AnaptysBio trade lawsuits over Jemperli |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .